By Christine A. Wu, Research Analyst, LSN
Large pharma companies are increasingly looking to early stage companies to fill their future pipelines. These firms have a variety of means of engaging with early stage companies, including in-licensing, collaborations, equity investments, and M&A. At RESI@TMCx, four senior external sourcing staff from the pharma world will explain what their firms are looking for, how they work with early stage companies, and how an emerging biotech company can position themselves to make a big pharma deal.
Moderated by Bill Kohlbrenner, CSO, Life Science Nation, the panelists are:
- Marc Schwabish, US Head, Pharma Business Development & Licensing, Bayer
- Barbara Araneo, Innovation Sourcing Director, Novo Nordisk
- Joseph Simeone, Director, Business Development & Licensing, Merck
- Mark Day, Executive Director, Head of External Research & Scouting, Alexion